**Materials for this course will be release on 04/15/2020**

Infectious Diseases Pharmacy Specialty Recertification Literature Study: Module 1A-B (Cert # L209147)

Teaser: The Literature Study Module provides immediate access to peer-selected, contemporary articles that are relevant to specialty practice. After learners review the content, they must successfully complete an online assessment to earn recertification credit.

Tag: Certifications; Infectious Disease

ACPE Numbers: Various – see listing below
Pre-Sale Date: 03/18/2020
Content Release Date: 04/15/2020
Expiration Date: 10/20/2020
Activity Type: Application-based
CE Credits: 8 hours (BPS and ACPE)
Activity Fee: $55 (ASHP member); $110 (non-member)

Accreditation for Pharmacists
The American Society of Health-System Pharmacists and American College of Clinical Pharmacy are accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Target Audience
These Literature Studies are designed to help board-certified pharmacists who are seeking recertification credit hours to maintain their Board of Pharmacy Specialties (BPS).

Activity Overview
The Literature Study Module is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of 2 online home study activities (see table below). Each activity is designed to assess the learners’ ability to analyze and apply peer-selected contemporary articles to.

Module 1A: HIV and Hepatitis C: This module focuses on pre- and post-exposure prophylaxis of HIV, as well as management of patients with HIV and/or Hepatitis C.

Module 1B: ID Potpourri: This module focuses on new information that is important to the infectious diseases pharmacist, including management of penicillin allergy, considering recombinant zoster vaccine in immunosuppressed patients, and prevention and management of tuberculosis.

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this Literature Study, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.

These activities are part of the ASHP and ACCP professional development program for BCIDP recertification approved by the BPS.
**Materials for this course will be release on 04/15/2020**

Recertification Credit*

Board certified pharmacists are eligible to receive up to 8 hours of recertification credit for completing this module. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

<table>
<thead>
<tr>
<th>Learning Activity</th>
<th>ACPE Number</th>
<th>Credit Hours</th>
<th>*Assessment Pass Point</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infectious Diseases Pharmacy Recertification Literature Study Module 1A: HIV and hepatitis C</td>
<td>0204-0000-20-944-H01-P</td>
<td>5.00</td>
<td>76%</td>
</tr>
<tr>
<td>Infectious Diseases Pharmacy Recertification Literature Study Module 1B: ID Potpourri</td>
<td>0204-0000-20-945-H01-P</td>
<td>3.00</td>
<td>75%</td>
</tr>
</tbody>
</table>

Articles and Learning Objectives

Module 1A: HIV and Hepatitis C
0204-0000-20-944-H01-P

This module focuses on pre- and post-exposure prophylaxis of HIV, as well as management of patients with HIV and/or Hepatitis C.


Learning Objectives:
- Explain the rationale, methodology, findings, limitations, and implications of the PARTNER study of the risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy.
- Develop recommendations for the use of suppressive antiretroviral therapy and condoms by serodifferent gay couples to protect against HIV transmission.


Learning Objectives:
- Explain the rationale, methodology, findings, limitations, and implications of the BRIEF TB/A5279 study of tuberculosis preventive therapy in patients with human immunodeficiency virus (HIV) infection.
- Develop recommendations for tuberculosis preventive therapy in high-risk patients with human immunodeficiency virus (HIV) infection.
Infectious Diseases Pharmacy Specialty
Recertification Literature Study

** Materials for this course will be release on 04/15/2020 **


Learning Objectives:

- Explain the rationale, methodology, findings, limitations, and implications of the EXPEDITION-2 study of glecaprevir coformulated with pibrentasvir in adults coinfected with hepatitis C virus (HCV) and human immunodeficiency virus type 1 (HIV-1).
- Develop recommendations for the use of glecaprevir coformulated with pibrentasvir in adults coinfected with hepatitis C virus (HCV) and human immunodeficiency virus type 1 (HIV-1).


Learning Objectives:

- Discuss recent progress and ongoing challenges in treating hepatitis C virus (HCV) infection in the United States and the recommended approach to diagnostic testing and treatment.
- Compare and contrast the mechanism of action, genotype coverage, duration of therapy, cost, efficacy, and adverse effects of recommended direct-acting antiviral (DAA) regimens for the initial treatment or retreatment of hepatitis C virus (HCV) infection.
- Develop recommendations for the diagnosis and management of hepatitis C virus (HCV), taking into consideration life expectancy, comorbid conditions, HCV genotype, and prior direct-acting antiviral (DAA) exposure.

Centers for Disease Control and Prevention. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV—United States, 2016. Including the Update: Interim Statement Regarding Potential Fetal Harm from Exposure to Dolutegravir – Implications for HIV Post-exposure Prophylaxis (PEP).

Learning Objectives:

- Describe the new recommendations in the 2016 updated guidelines from the Centers for Disease Control and Prevention (CDC) for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV.
- Develop recommendations for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV.

Module 1B: ID Potpourri
0204-0000-20-945-H01-P

This module focuses on new information that is important to the infectious diseases pharmacist, including management of penicillin allergy, considering recombinant zoster vaccine in immunosuppressed patients, and prevention and management of tuberculosis.


Learning Objectives:

- Explain the rationale, methodology, findings, limitations, and implications of the Zoster Efficacy Study in Patients Undergoing HSCT (ZOE-HSCT)
** Materials for this course will be release on 04/15/2020 **

- Develop recommendations for the use of recombinant zoster vaccine in adults undergoing autologous hematopoietic stem cell transplantation
- Compare and contrast the appropriate use of recombinant zoster vaccine and zoster vaccine live in adults


Learning Objectives:
- Describe the epidemiology of penicillin allergy, clinical consequences of labeling patients as penicillin allergic, and methods for clinically evaluating patients with a report of penicillin allergy
- Develop a plan for the clinical evaluation of patients with a report of penicillin allergy


Learning Objectives:
- Describe the impetus for, methodology used, and nature of the changes in the 2019 recommendations from the National Tuberculosis Controllers Association and Centers for Disease Control and Prevention for tuberculosis screening, testing, and treatment of health care personnel
- Develop recommendations for tuberculosis (TB) screening, testing, and treatment of health care personnel (HCP), including baseline screening, testing, and individual TB risk assessment; postexposure screening and testing; serial screening and testing for HCP without latent TB infection (LTBI); and evaluation and treatment of positive test results


Learning Objectives:
- Explain the rationale, methodology, limitations, and implications of the study of the risk of relapse in patients with tuberculosis based on the drug minimum inhibitory concentration for the *Mycobacterium tuberculosis* isolate compared with the standard resistance breakpoint.
- Discuss the model created by Colangeli and colleagues for predicting the risk of relapse in patients with tuberculosis.

Faculty
Heather Cox Hall, Pharm.D., BCPS-AQID, BCIDP
Lead Pharmacist, Infectious Diseases
University of Virginia Health System
Charlottesville, VA

Steve C. Ebert, B.S.Pharm., Pharm.D., FCCP, FIDSA, BCIDP
Clinical Pharmacy Manager, Infectious Diseases
Department of Pharmacy
UnityPoint Health-Meriter Hospital
Madison, WI
** Materials for this course will be release on 04/15/2020 **

Sarah M. Michienzi, Pharm.D., BCPS, AAHIVP  
Clinical Assistant Professor  
Department of Pharmacy Practice  
College of Pharmacy  
University of Illinois at Chicago  
Chicago, IL

Trent G. Towne, Pharm.D., BCPS  
Associate Professor of Pharmacy Practice  
Manchester University College of Pharmacy  
Fort Wayne, IN

Content Matter Experts  
Snehal Bhatt, Pharm.D., BCPS  
Associate Professor of Pharmacy Practice  
Massachusetts College of Pharmacy and Health Science  
Clinical Pharmacist  
Beth Israel Deaconess Medical Center  
Boston, Massachusetts

Kevin Garey, Pharm.D., M.S., FASHP  
Professor and Chair  
University of Houston  
Houston, Texas

Jason Schafer, Pharm.D., M.P.H., AAHIVP, BCPS  
Associate Professor, Department of Pharmacy Practice  
Jefferson College of Pharmacy, Thomas Jefferson University  
Philadelphia, Pennsylvania

Douglas Slain, Pharm.D., B.S.Pharm., BCPS, FASHP  
Professor and Infectious Diseases Clinical Specialist  
West Virginia University (WVU) and WVU Hospitals and Clinics  
Canonsburg, Pennsylvania

Kayla Stover, Pharm.D., BCIDP, BCPS-AQ ID, FCCP, FIDSA  
Associate Professor  
University of Mississippi School of Pharmacy  
Jackson, MS

Evan Zasowski, Pharm.D., M.P.H., BCPS  
Clinical Assistant Professor  
University of Houston College of Pharmacy  
Houston, Texas

Reviewers  
Susan R. Dombrowski, M.S., R.Ph.  
Kristi Hofer, Pharm.D.
**Materials for this course will be release on 04/15/2020**

**Field Testers**
Sharon Blum, Pharm.D., BCIDP
Kimberly Boeser, Pharm.D., MPH, BCIDP
John Boreyko, Pharm.D, BCIDP
Andrea Boyce, Pharm.D., BCIDP
Robin Bricker-Ford, Pharm.D., BCIDP, BCPS, AAHIVP
Maureen Campion, Pharm.D., BCIDP
Erika Ernst, Pharm.D., BCIDP
Stuart Greaser, Pharm.D., BCPS, BCIDP
Tara Lines, Pharm.D., BDICP
Kari Mergenhagen, Pharm.D., BCPS, BCIDP
Jessica Miller, Pharm.D., BCIDP
Mallory Noriega, Pharm.D., BCPS, BCIDP
Angela Perhac, Pharm.D., BCIDP
Leonor Rojas, Pharm.D., BCIDP, BCPS
Lucas Schulz, Pharm.D. BCIDP
Stephanie Shulder, Pharm.D., BCIDP
Rand Sulaiman, Pharm.D, BCIDP
Jessica Thompson, Pharm.D., BCPS, BCIDP
Mary Ullman, Pharm.D., BCPS, BCIDP
Hana Winders, Pharm.D., BCIDP

**Disclosures**
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP and ACCP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual or his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

All faculty and planners for ASHP and ACCP education activities are qualified and selected by ASHP and ACCP, are required to disclose any relevant financial relationships with commercial interests. ASHP and ACCP identify and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

- Sarah M. Michienzi: Merck, Research Grant Recipient
- Kevin Garey: Merck & Co., Research Grant Recipient
- Jason Schafer: Merck & Co, Research Grant Recipient and Advisory Board; Gilead, Research Grant Recipient

All other planners, presenters, and reviewers and others with an opportunity to control content report no financial relationships relevant to this activity.
Methods and CE Requirements
Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

- Complete the attestation statement
- Review all content
- Complete and pass the assessments
- Complete the evaluations

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

System Technical Requirements
Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites.

View the minimum technical and system requirements for learning activities.

Development
These activities were developed by ASHP and ACCP.